Preventing thrombophilia-related complications of pregnancy

References

• Robertson L, Wu O, Langhorne P et al.; for the Thrombosis: Risk and Economic assessment of Thrombophilia Screening (TREATS) Study. Thrombophilia in pregnancy: a systematic review. Br. J. Haematol.132, 171–196 (2005).
   Web of Science ®Google Scholar
• Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost.4, 294–306 (2006).
   Google Scholar
• Bertina RM, Koeleman RPC, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature369, 64–67 (1994).
   PubMed Web of Science ®Google Scholar
• Rees D. The population genetics of factor V Leiden. Br. J. Haematol.95, 579–586 (1996).
   PubMedGoogle Scholar
• Dahlback B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood112, 19–27 (2008).
   PubMed Web of Science ®Google Scholar
• Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3´ untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood88, 3698–3703 (1996).
   PubMed Web of Science ®Google Scholar
• Perry DJ. Antithrombin and its inherited deficiencies. Blood Rev.8, 37–55 (1994).
   PubMedGoogle Scholar
• Pierangeli SS, Chen PP, Raschi E et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin. Thromb. Hemost.34, 236–250 (2008).
   PubMed Web of Science ®Google Scholar
• Bick RL. Antiphospholipid syndrome in pregnancy. Hematol. Oncol. Clin. North Am.22, 107–120 (2008).
   PubMed Web of Science ®Google Scholar
• Pomp ER, Lenselink AM, Rosendaal FR, Doggen CI. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J. Thromb. Haemost.6, 632–637 (2008).
   PubMed Web of Science ®Google Scholar
• Ageno W, Squizzato A, Garcia D, Imberti D. Epidemiology and risk factors of venous thromboembolism. Semin. Thromb. Hemost.32, 651–658 (2006).
   PubMed Web of Science ®Google Scholar
• Gherman RB, Goodwin TM, Leung B, Byrne JD, Hethumumi R, Montoro M. Incidence, clinical characteristics and timing of objectively diagnosed venous thromboembolism during pregnancy. Obstet. Gynecol.94, 730–734 (1999).
   PubMed Web of Science ®Google Scholar
• James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors and mortality. Am. J. Obstet. Gynecol.194, 1311–1315 (2006).
   PubMed Web of Science ®Google Scholar
• Ikard RW, Ueland K, Folse R. Lower limb venous dynamics in pregnant women. Surg. Gynceol. Obstet.132, 483–488 (1971).
   PubMedGoogle Scholar
• Macklon NS, Greer IA, Bowman AW. An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy. Br. J. Obstet. Gynecol.102, 191–197 (1997).
   Google Scholar
• Goodrich SM, Wood JE. Peripheral venous distensibility and velocity of venous blood during pregnancy or during oral contraceptive therapy. Am. J. Obstet. Gynecol.90, 740–744 (1964).
   PubMedGoogle Scholar
• Cerneca F, Ricci G, Simeone R, Malisano M, Alberico S, Guashino S. Coagulation and fibrinolysis changes in normal pregnancy. Increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis. Eur. J. Obstet. Gynecol.73, 31–36 (1997).
   PubMed Web of Science ®Google Scholar
• Brill-Edwards P, Ginsberg JS, Gent M et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. N. Engl. J. Med.343, 1439–1444 (2000).
   PubMed Web of Science ®Google Scholar
• Ray JS, Chan WS. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. Obstet. Gynecol. Surv.54, 265–271 (1999).
   PubMedGoogle Scholar
• Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ 3rd. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann. Intern. Med.143, 697–706 (2005).
   PubMed Web of Science ®Google Scholar
• Dizon-Townson D, Miller C, Sibai B et al. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus. Obstet. Gynecol.106, 517–524 (2005).
   PubMed Web of Science ®Google Scholar
• McColl M, Ramsay JE, Tait RC et al. Risk factors for pregnancy-associated venous thromboembolism. Thromb. Haemost.78, 1183–1188 (1997).
   PubMed Web of Science ®Google Scholar
• Vossen CY, Conard J, Fontcuberta J et al. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect: the European Prospective Cohort on Thrombophilia (EPCOT). J. Thromb. Haemost.3, 459–464 (2005).
   PubMed Web of Science ®Google Scholar
• Lensen RP, Bertina RM, de Ronde H, Vandenbroucke JP, Rosendaal FR. Venous thrombotic risk in family members of unselected individuals with factor V Leiden. Thromb. Haemost.83, 817–821 (2000).
   PubMed Web of Science ®Google Scholar
• Pabinger I, Grafenhofer H, Kyrle PA et al. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood100, 1060–1062 (2002).
   PubMed Web of Science ®Google Scholar
• De Stefano V, Martinelli I, Rossi E et al. The risk of recurrent venous thromboembolism in pregnancy and the puerperium without antithrombotic prophylaxis. Br. J. Haematol.135, 386–391 (2006).
   PubMed Web of Science ®Google Scholar
• Pabinger I, Grafenhofer H, Kaider A et al. Risk of pregnancy associated recurrent venous thromboembolism in women with a history of venous thrombosis. J. Thromb. Haemost.3, 949–954 (2005).
   PubMed Web of Science ®Google Scholar
• Greer IA. Thrombophilia: implications for pregnancy outcome. Thromb. Res.109, 73–81 (2003).
   PubMed Web of Science ®Google Scholar
• Hossain N, Paidas M. Adverse pregnancy outcome, the uteroplacental interface, and preventive strategies. Semin. Perinatol.31, 208–212 (2007).
   PubMed Web of Science ®Google Scholar
• Redline R. Thrombophilia and placental pathology. Clin. Obstet. Gynecol.49, 885–894 (2006).
   PubMed Web of Science ®Google Scholar
• Gupta S, Agarwal A, Banerjee J, Alvarez JG. The role of oxidative stress in spontaneous abortion and recurrent pregnancy loss: a systematic review. Obstet. Gynecol. Surv.62, 335–347 (2007).
   PubMed Web of Science ®Google Scholar
• Rand JH, Wu XX, Andree H et al. Pregnancy loss in the antiphospholipid antibody syndrome: possible thrombogenic mechanisms. N. Engl. J. Med.336, 154–160 (1997).
   Google Scholar
• Stirrat GM. Recurrent miscarriage I: definition and epidemiology. Lancet336, 673–675 (1990).
   PubMed Web of Science ®Google Scholar
• Kovalevsky G, Gracia CR, Berlin JA, Sammel MD, Barnhart KT. Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss: a meta-analysis. Arch. Int. Med.164, 558–563 (2004).
   PubMed Web of Science ®Google Scholar
• Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet361, 901–908 (2003).
   PubMed Web of Science ®Google Scholar
• Dudding T, Heron J, Thakkinstian A et al. Factor V Leiden is associated with pre-eclampsia but not with fetal growth restriction: a genetic association study and meta-analysis. J. Thromb. Haemost.6, 1868–1875 (2008).
   Google Scholar
• Hefler L, Jirecek S, Heim K et al. Genetic polymorphisms associated with thrombophilia and vascular disease in women with unexplained late intrauterine fetal death: a multicentre study. J. Soc. Gynecol. Investig.11, 42–44 (2004).
   PubMedGoogle Scholar
• Yasuda M, Takakuwa K, Tokunaga A, Tanaka K. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet. Gynecol.86, 555–559 (2005).
   Google Scholar
• Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur. J. Obstet. Gynecol. Reprod. Biol.101, 6–14 (2002).
   PubMed Web of Science ®Google Scholar
• Lin J, August P. Genetic thrombophilias and preeclampsia: a meta-analysis. Obstet. Gynecol.105, 182–192 (2005).
   PubMed Web of Science ®Google Scholar
• Mello G, Parretti E, Marozio L et al. Thrombophilia is significantly associated with severe preeclampsia. Hypertension46, 1270–1274 (2005).
   PubMed Web of Science ®Google Scholar
• Sibai B. Thrombophilia and severe preeclampsia: time to screen and treat in future pregnancies? Hypertension46, 1252–1253 (2005).
   PubMed Web of Science ®Google Scholar
• Sinha P, Kuruba N. Ante-partum haemorrhage: an update. J. Obstet. Gynecol.28, 377–381 (2007).
   Google Scholar
• Ananth CV, Berkowitz GS, Savitz DA, Lapinski RH. Placental abruption and adverse perinatal outcomes. JAMA282, 1646–1651 (1999).
   PubMed Web of Science ®Google Scholar
• Kramer MS. Determinants of low birth weight: methodological assessment and meta-analysis. Bull. World Health Organ.65, 663–737 (1987)
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Marozio L, Grandone E, Pizzi C, Volpe A, Benedetto C. Thrombophilic mutations are a main risk factor for placental abruption. Haematologica88, 785–788 (2003).
   PubMed Web of Science ®Google Scholar
• Prochazka M, Lubusky M, Slavik L et al. Frequency of selected thrombophilias in women with placental abruption. Aust. NZ J. Obstet. Gynaecol.47, 297–301 (2007).
   PubMed Web of Science ®Google Scholar
• Howley HE, Walker M, Rodger MA. A systematic review of the association between factor V Leiden or prothrombin gene variant and intrauterine growth restriction. Am. J. Obstet. Gynecol.192, 694–708 (2005).
   PubMed Web of Science ®Google Scholar
• Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest133, 844–886 (2008).
   PubMed Web of Science ®Google Scholar
• Hall JAG, Paul RM, Wilso KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am. J. Med.68, 122–140 (1968).
   Google Scholar
• Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systemic review of the literature. Arch. Intern. Med.160, 191–196 (2000).
   PubMedGoogle Scholar
• Flessa HC, Kapstrom AB, Gluck HI, Will JJ, Miller MA, Brinker BL. Placental transport of heparin. Am. J. Obstet. Gynecol.93, 570–573 (1965).
   PubMed Web of Science ®Google Scholar
• Forrestier F, Caffos F, Capella-Pavlovsky M. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy: study by direct fetal blood sampling under ultrasound. Thromb. Res.34, 557–560 (1984).
   PubMedGoogle Scholar
• Lindhoff-Last E, Bauersachs R. Heparin-induced thrombocytopenia – alternative anticoagulation in pregnancy and lactation. Semin. Thromb. Haemost.28, 439–445 (2002).
   PubMed Web of Science ®Google Scholar
• Lagrange F, Vergnes C, Brun JL et al. Absence of placental transfer of pentasaccharide (Fondaparinux, Arixtra) in the dually perfused human cotyledon in vitro. Thromb. Haemost.87, 831–835 (2002).
   PubMed Web of Science ®Google Scholar
• Dempfle CE. Minor transplacental passage of fondaparinux in vivo. N. Engl. J. Med.350, 1914–1915 (2004).
   PubMed Web of Science ®Google Scholar
• Mazzolai L, Hohfeld P, Spertini F, Hayoz D, Schapira M, Duchasal MA. Fondparinux is a safe alternative in case of heparin intolerance during pregnancy. Blood108, 1569–1579 (2006).
   PubMed Web of Science ®Google Scholar
• Greer IA, Nelson-Piercy C. Low molecular weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood.106, 401–407 (2005)
   PubMed Web of Science ®Google Scholar
• Weitz JI. Low-molecular-weight heparin. N. Engl. J. Med.337, 688–698 (1997).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Greinacher A, Koster A, Lincoff. M. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Guidelines (8th Edition). Chest133(Suppl.), S340–S380 (2008).
   PubMedGoogle Scholar
• Carlin AJ, Farquharson RG, Quenby SM, Topping J, Fraser WD. Prospective observational study of bone mineral density during pregnancy: low-molecular-weight heparin versus control. Hum. Reprod.19, 1211–1214 (2004).
   PubMed Web of Science ®Google Scholar
• Anderson DR, Ginsberg JS, Burrows R, Brill-Edwards P. Subcutaneous heparin therapy during pregnancy: a need for concern at the time of delivery. Thromb. Haemost.65, 248–250 (1991).
   PubMedGoogle Scholar
• O’Donnell MJ, Kearon C, Johnson J et al. Brief communication: preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. Ann. Intern. Med.146, 184–187.
   Google Scholar
• Holst J, Lindblad B, Bergqvist D et al. Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (Tinzaparin, Logiparin). An experimental investigation in healthy volunteers. Blood Coagul. Fibrinolysis5, 795–780 (1994).
   PubMedGoogle Scholar
• Frozovi K, Deveras AE, Kessler CM. Reversal of low-molecular-weight heparin-induced bleeding in patients with pre-existing hypercoagulable states with human recombinant activated factor VIIa. Am. J. Hematol.81, 582–589 (2006).
   PubMedGoogle Scholar
• Horlocker TT, Wedel DJ, Benzon H et al. Regional anesthesia in the anticoagulated patient: defining the risks (the Second ASRA Consensus Conference on Neuroaxial Anesthesia and Anticoagulation). Reg. Anesth. Pain Med.28, 172–179 (2003).
   PubMed Web of Science ®Google Scholar
• McKenna R, Cole ER, Vasan V. Is warfarin sodium contraindicated in the lactating mother? J. Pediatr.103, 325–327 (1983).
   PubMed Web of Science ®Google Scholar
• Orme ML, Lewis PJ, de Swiet M et al. May mothers given warfarin breast-feed their infants? BMJ1, 1564–1565 (1977).
   PubMed Web of Science ®Google Scholar
• O’Reilly R. Anticoagulant, antithrombotic and thrombolytic drugs. In: The Pharmacological Basis of Therapeutics (6th Edition). Gillman AG, Rall W, Nies AS, Taylor P (Eds). Macmillan, NY, USA 1347 (1980).
   Google Scholar
• Richter C, Sitzmann J, Lang P, Wietzel H, Huch A, Huch R. Excretion of low-molecular-weight heparin in human milk. Br. J. Clin. Pharmacol.52, 708–710 (2001).
   PubMed Web of Science ®Google Scholar
• Coomarasamy A, Honest H, Papaioannou S, Gee H, Khan KS. Aspirin for prevention of pre-eclampsia in women with historical risk factors: a systematic review. Obstet. Gynecol.101, 1319–1332 (2003).
   PubMed Web of Science ®Google Scholar
• Kozer E, Costei AM, Boskovic R, Nulman I, Nikfar S, Koren G. Effects of aspirin consumption during pregnancy on pregnancy outcomes: meta-analysis. Birth Defects Res. B Dev. Reprod. Toxicol.68, 70–84 (2003).
   PubMedGoogle Scholar
• Kozer E, Nikfar S, Costei A, Boskovic R, Nulman I, Koren G. Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Am. J. Obstet. Gynecol.156, 1623–1630 (2002).
   Google Scholar
• James AH, Brancazio LR, Price T. Aspirin and reproductive outcomes. Obstet. Gynecol. Surv.63, 49–57 (2007).
   Google Scholar
• Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet355, 1295–1302 (2000).
   PubMed Web of Science ®Google Scholar
• Glynn RJ, Ridker PM, Goldhaber SZ, Buring JE. Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. Ann. Intern. Med.147, 525–533 (2007).
   PubMed Web of Science ®Google Scholar
• Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst. Rev.2, CD002859 (2005)
   Google Scholar
• Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet. Gynecol.100, 408–413 (2002)
   PubMed Web of Science ®Google Scholar
• Stephenson MD, Ballem PJ, Tsang P et al. Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. J. Obstet. Gynaecol. Can.26, 729–734 (2004).
   PubMedGoogle Scholar
• Noble LS, Kutteh WH, Lashey N, Franklin RD, Herrada J. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective multicentre controlled pilot study comparing treatment with low molecular weight heparin versus unfractionated heparin. Fertil. Steril.83, 694–690 (2005).
   Google Scholar
• Hutton B, Sharma R, Fergusson D et al. Use of intravenous immunoglobulin for treatment or recurrent miscarriage: a systematic review. Br. J. Obstet. Gynecol.114, 134–142 (2007).
   Google Scholar
• El Haieg DO, Zanati MF, El-Foual FM. Plasmapheresis and pregnancy outcome in patents with antiphospholipid syndrome. Int. J. Gynecol. Obstet.99, 236–241 (2007).
   PubMedGoogle Scholar
• Grandone E, De Stefano V, Rossi E, Cappucci F, Colaizzo D, Margaglione Ml. Antithrombotic prophylaxis during pregnancy in women with deficiency of natural anticoagulants. Blood Coagul. Fibrinolysis19, 226–230 (2008).
   PubMed Web of Science ®Google Scholar
• Folkeringa N, Brouwer JL, Korteweg FJ et al. Reduction of high fetal loss rate by anticoagulant treatment during pregnancy in antithrombin, protein C or protein S deficient women. Br. J. Haematol.136, 656–661 (2007).
   PubMed Web of Science ®Google Scholar
• Dendrinos S, Kalogirou I, Makrakis E et al. Safety and effectiveness of tinzaparin sodium in the management of recurrent pregnancy loss. Clin. Exp. Obstet. Gynecol.34, 143–145 (2007).
   PubMed Web of Science ®Google Scholar
• Carp H, Dolitzky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J. Thromb. Haemost.1, 433–438 (2003).
   PubMed Web of Science ®Google Scholar
• De Carolis S, Ferrazzani S, de Stefano V et al. Inherited thrombophilia: treatment during pregnancy. Fetal Diagn. Ther.21, 281–286 (2006).
   PubMed Web of Science ®Google Scholar
• Ghosh K, Shetty S, Vora S. Successful pregnancy outcome in women with bad obstetric history and recurrent fetal loss due to thrombophilia: effect of unfractionated heparin and low-molecular weight heparin. Clin. Appl. Thromb. Hemost.14, 174–179 (2008).
   PubMedGoogle Scholar
• Gris JC, Mercier E, Quere I, Lavigne-Lissalde G, Cochery-Nouvellon E, Hoffet M. Low molecular weight heparin versus low dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood103, 3695–3699 (2004).
   PubMed Web of Science ®Google Scholar
• Brenner B, Bar J, Ellis M et al. Effects of enoxaparin on late pregnancy complications and neonatal outcome in women with recurrent pregnancy loss and thrombophilia: results from the LIVE-ENOX study. Fertil. Steril.84, 770–773 (2005).
   PubMed Web of Science ®Google Scholar
• Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst. Rev.2, CD004659 (2007).
   PubMed Web of Science ®Google Scholar
• Askie LM, Duley L, Henderson-Smart D, Stewart LA; for the Paris Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet369, 1791–1798 (2007).
   PubMed Web of Science ®Google Scholar
• Riyazi N, Leeda M, de Vries J, Huijgens PC, van Geijn HP, Dekker GA. Low molecular weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. Eur. J. Obstet. Gynecol. Reprod. Biol.80, 49–54 (1998).
   PubMed Web of Science ®Google Scholar
• Kalk JJ, Huisjes AJ, de Groot CJ et al. Recurrence rate of pre-eclampsia in women with thrombophilia influenced by low molecular weight heparin treatment? Neth. J. Med.62, 83–87 (2004).
   PubMedGoogle Scholar
• Wu O, Robertson L, Twaddle S et al. Screening for thrombophilia in high-risk situations: systematic review and cost–effectiveness analysis. Health Technol. Assess.10, 1–110 (2006).
   PubMed Web of Science ®Google Scholar
• Gates S, Brocklehurst P, Ayers S, Bowler U; Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low-molecular-weight heparin. Am. J. Obstet. Gynecol.191, 1296–1303 (2004).
   PubMedGoogle Scholar
• Leduc L, Dubois E, Takser L, Rey E, David M. Dalteparin and low dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. J. Obstet. Gynaecol. Can.29, 787–793 (2007).
   PubMedGoogle Scholar
• Grandone E, Brancaccio V, Colaizzo D et al. Preventing adverse obstetric outcomes in women with genetic thrombophilia. Fertil. Steril.78, 371–375 (2002).
   PubMed Web of Science ®Google Scholar
• Kupferminc MJ, Fait G, Many A et al. Low-molecular-weight-heparin for the prevention of obstetric complications in women with thrombophilias. Hypertens. Pregnancy20, 35–44 (2001).
   PubMed Web of Science ®Google Scholar